CBChristina Barmpagianni

Christina Barmpagianni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christina Barmpagianni has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Paediatric supracondylar humeral fractures: assessment and management

    by Themistoklis Vampertzis, Suraj Kohli, Emmanuel Spanoudakis, Panagiotis Sgardelis, Athanasios Serlis, Christina Barmpagianni, Darius Rares Rad, Farokh Wadia

    This paper aims to provide a structured approach to managing supracondylar humerus fractures in the paediatric population, informed by the most recent literature and guidelines. It aims to prepare candidates for the specialist examination in trauma and orthopaedic (e.g. Fellowship of the Royal College of Surgeons (FRCS), Fellowship of the European Board of Orthopaedics and Traumatology (FEBOT), Board Exams, etc.) while also emphasising important considerations for practitioners who may not frequently encounter paediatric supracondylar fractures.


  • Open Access

    Botulinum toxin in fracture management: a scoping review

    by Emmanuel Spanoudakis, Themistoklis Vampertzis, Farokh Wadia, Darius Rares Rad, Christina Barmpagianni, Ioannis A Zervos, Eleftherios Tsiridis, Nikiforos Galanis

    Purpose: Using botulinum toxin (BoNT) as an adjunct in fracture management is a novel approach with the potential to improve clinical outcomes, particularly in atypical fractures and patients with concurrent neuromuscular disorders. This scoping review explores the literature on BoNT’s effectiveness in facilitating fracture healing and immobilisation across various fracture types. Methods: The PubMed, Embase, and Cochrane databases were searched with defined operators. Two investigators conducted independent searches, which were combined. Animal studies, case reports, case series, cohort reviews and randomised control trials were included. Results: Fifty studies were identified for screening, from which 15 studies were included in the review. The findings highlight mixed outcomes in BoNT’s role in enhancing bone healing and reducing muscle-induced displacement. While BoNT injections demonstrated potential benefits in specific cases, such as atypical fractures, periprosthetic fractures and fractures in patients with motor dysfunctions, results from animal studies were inconsistent, showing varied effects on callous formation and bone mineral density. Conclusion: Clinical applications of BoNT in fracture management indicate its utility as an immobilisation agent to promote fracture healing and reduce complications. However, this review highlights that further research is necessary to bridge the gap between experimental and clinical studies and to clarify BoNT’s effectiveness in different use cases.